Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06439654 · ClinicalTrials.gov registry record · NA
Atlantic Lipid Lowering Treatment Optimization Program
A NA study of Familial Hypercholesterolemia and Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, sponsored by Atlantic Health System.
- Recruiting
- Registry status
- NA
- Development phase
- 250
- Enrollment target
- 2
- Study locations
NCT06439654 is a NA study of Familial Hypercholesterolemia and Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia that is actively recruiting participants, run by Atlantic Health System. The registered enrollment target is 250 participants, above the 191-participant average among 7 other Familial Hypercholesterolemia trials with a reported enrollment target (31% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT06439654, a NA study of Familial Hypercholesterolemia and Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, is actively recruiting participants, sponsored by Atlantic Health System.
- RECRUITING
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
- 2
- Study locations
Study Summary
Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D. Fishberg, MD, and Jeffrey N. Feldman, MD. The overarching goal of the lipid workgroup is to enhance the treatment of lipid disorders in those patients with abnormal lipid levels by improving access to resources at the primary care practice level and specialty level. We aim to develop a model for primary and secondary prevention that integrates guidelines for treatment at the practice level. Our primary objective is to identify high-risk patients by utilizing the electronic health record and partnering with patients' primary care providers to provide comprehensive medical management.
Conditions Studied
Interventions
- OTHER Supportive care
Study Locations (2)
New Jersey
- Atlantic Medical Group - Clark
- Atlantic Medical Group - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06439654
The ClinicalTrials.gov registry entry for NCT06439654 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 191-participant average among 7 other Familial Hypercholesterolemia trials with a reported enrollment target (31% higher). The listed sponsor is Atlantic Health System, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Familial Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which Supportive care is the first listed.
NCT06439654 reports 2 study locations spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06439654 about?
NCT06439654 is a clinical study titled "Atlantic Lipid Lowering Treatment Optimization Program". Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D. Fishberg, MD, and Jeffrey N. Feldman, MD. The overarching goal of the lipid workgroup i...
What is the current status of trial NCT06439654?
This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2024-07-01. Estimated completion is 2027-12-31.
What conditions does trial NCT06439654 study?
This clinical trial studies the following conditions: Familial Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, Apolipoprotein B 100, Familial Defective, High Density Lipoprotein Deficiency, Low-Density-Lipoid-Type Hyperlipoproteinemia.
What interventions are being tested in trial NCT06439654?
The interventions under investigation include: Supportive care (OTHER).
Who is sponsoring clinical trial NCT06439654?
This trial is sponsored by Atlantic Health System, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06439654 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Familial Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The ORIGIN-FH Study
RECRUITING · NA
-
Comparing Direct vs Indirect Methods for Cascade Screening
RECRUITING · NA
-
2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)
RECRUITING · Phase 2
-
Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)
ACTIVE NOT RECRUITING · Phase 3
-
Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers
COMPLETED
-
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
COMPLETED · Phase 3
Explore more on PlainTrial
Familial Hypercholesterolemia
All registered trials for this condition
Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia
All registered trials for this condition
New Jersey
All trials with a study site in New Jersey
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.